Despite the recent approval of lamivudine for the treatment of children with chronic hepatitis B virus (HBV) infection, there is insufficient information on the kinetics of HBV clearance and the factors that predict a favorable treatment response to lamivudine in this population. In a small retrospective study of 16 HBVinfected children treated with lamivudine, we examined changes in virus load and other factors associated with hepatitis B e antigen (HBeAg) clearance. High pretherapy alanine aminotransferase level, low serum HBV DNA load, and age at the start of treatment were independently associated with HBeAg clearance. HBeAg clearance was also associated with the achievement of specific levels of virus suppression, and failure to achieve those levels was associated with the development of lamivudine resistance. Additional studies are necessary to provide better indications and guidelines for the treatment of children with chronic HBV infection.
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Chronic hepatitis B virus (HBV) infection remains a serious public health problem, despite the availability of a safe and effective vaccine. With an estimated 400 million carriers of chronic HBV worldwide, HBV is the leading cause of cirrhosis and hepatocellular carcinoma [1] . In the United States, this problem is often unrecognized in immigrants from countries where HBV infection is endemic. Children with chronic HBV infection who were either infected perinatally or during early childhood have a significant lifetime risk of developing cirrhosis and hepatocellular carcinoma [2] . Although these severe complications of chronic liver disease usually do not present during childhood [3] , the development of new treatments for chronic HBV infection provides hope that early treatment of childhood infection could decrease the long-term morbidity among adults.
However, the treatment of chronic HBV infection in children remains controversial, with few consensus guidelines. This controversy is a result of the nature of the manifestations of hepatitis B in children, the limited efficacy of currently recommended treatment, and the frequent adverse side effects associated with treatments. Chronic HBV infection in children tends to be milder than infection in adults. Most children-in particular, those who have acquired HBV infection perinatallyhave an asymptomatic clinical course with relatively normal serum alanine aminotransferase (ALT) levels. IFN-a, until recently the only drug approved for the treatment of chronic HBV infection in children, proved to be ineffective for the large majority of children, especially those children infected perinatally or during early childhood [4] . Furthermore, IFN-a was admin-istered by subcutaneous injection and was often accompanied by side effects that negatively affected acceptance of and compliance with this treatment, limiting its use to only the more seriously affected children.
Lamivudine, the (Ϫ) enantiomer of 3 -thiacytidine, is a safe and well-tolerated oral nucleoside analogue that selectively and competitively inhibits viral polymerases. Originally tested and approved for the treatment of HIV infection in adults and children in 1995 [5] , lamivudine was later shown to be effective in the treatment of chronic HBV infection and was approved for this indication in adults in 1998 [6] . Two-and-one-half years later, in 2001, it was approved for use in HBV-infected children aged 12 years. With the exception of a recent clinical trial involving children [7] that demonstrated that the efficacy of lamivudine is comparable with that of IFN-a, data on the use of lamivudine for treating HBV-infected children remains very limited [8, 9] . The excellent therapeutic profile and ease of administration of lamivudine will make it a more popular choice for treating children with chronic HBV infection. However, well-defined guidelines for treating such children have not been formulated. More information on the clinical, biochemical, and virological factors that are associated with a successful treatment outcome is urgently needed to identify those children who will most likely benefit from lamivudine treatment. In this study, we report our experience with the use of lamivudine to treat children with chronic HBV infection, focusing on the clinical, virological, and laboratory factors associated with a favorable therapeutic outcome.
PATIENTS AND METHODS

Patients.
This retrospective study included children with chronic HBV who were observed by the Infectious Diseases Service at Bellevue Hospital (New York) and had received treatment for chronic HBV infection with lamivudine between June 1999 and December 2001. Only children with elevated ALT levels were considered for treatment. Decisions to treat were made by individual treating physicians, and the interval between follow-up appointments varied among physicians.
HBV serological testing (performed by Quest Laboratories using assays manufactured by DiaSorin), including tests for measurement of hepatitis B e antigen (HBeAg) and hepatitis B e antibody (HBeAb) levels, ALT levels, and HBV DNA load, were performed at the start of treatment and, generally, every month for the first 3 months after initiation of therapy and every 2-3 months thereafter. Additional laboratory evaluations, including measurement of total and direct bilirubin levels, total protein and albumin levels, and complete blood cell counts, were performed. Serum HBV DNA loads were measured by quantitative real-time PCR with primers that amplify a highly conserved region of the surface gene [10] and with a detection system that employed molecular beacon technology [11] . The assay was calibrated using international HBV standards and a plasmid control containing a full-length cloned copy of HBV ayw. The assay has a 7 log 10 linear response, with a lower limit of detection of 200 copies/mL and an intraassay coefficient of variability of 15%.
Lamivudine was prescribed at a dosage of 3 mg/kg body weight per day, with a maximum dose of 150 mg daily. Treatment was continued until HBeAg seroconversion or evidence of clinical resistance occurred.
Data collection and analysis. Clinical and laboratory data, including data for adverse events, were extracted from medical charts, after which all personal identifiers were removed from the data set. To adequately ascertain treatment effect, only children who had been observed for at least 12 months after the time of initiation of treatment were included in this study. End points of analysis included HBeAg seroconversion, which was defined as clearance of HBeAg and suppression of serum HBV DNA levels to !10 5 copies/mL; decrease in virus load; and clinical resistance, defined as a return to baseline virus loads after a period of virus suppression.
Univariate statistical analyses with Student's t test (nonparametric equivalent), x 2 test, and Fisher's exact 2-sided test were used to examine differences in demographic and clinical characteristics between patients who did or did not undergo HBeAg seroconversion. Multivariate analyses, such as logistic regression and discriminant analysis, were conducted. Logistic regression was used to assess the factors that predicted seroconversion. Discriminant analysis was used to characterize a single dimension that would maximally and statistically distinguish seroconverters from nonseroconverters on the basis of variables demonstrated to be statistically significant in the univariate analysis [12] . Statistical analysis was performed with SPSS software, version 9.0 (SPSS).
This study was approved by the Institutional Review Boards of New York University School of Medicine and Bellevue Hospital. A waiver was obtained for the documentation of informed consent, in conformity with the guidelines for human experimentation established by the US Department of Health and Human Services.
RESULTS
Patient Population
Twenty-five children had begun treatment with lamivudine between June 1999 and December 2001. Only the 16 children who had been observed for at least 12 months after the start of treatment-a sufficient amount of time to assess treatment outcome-were included in this analysis. The 9 children who were not included had all received !6 months of treatment at the time of this analysis. All participants tested positive for hepatitis B surface antigen at least 6 months before treatment, had detectable HBeAg levels and HBV DNA loads at the start of treatment, and had elevated ALT levels within 3 months before starting treatment. None of the children had clinical evidence of cirrhosis. Ten children underwent liver biopsy before initiating treatment. Examination of liver biopsy specimens obtained from all 10 children showed evidence of chronic hepatitis, and no specimens showed evidence of cirrhosis. None of the children were coinfected with HIV or hepatitis C virus (HCV). One child had previously received treatment with IFN-a but failed to clear HBeAg. The median follow-up time after discontinuation of treatment was 12 months (range, 6-20 months).
Characteristics of Patients at the Start of Lamivudine Treatment
Baseline demographic characteristics and clinical, biochemical, and virological features of the 16 children treated with lamivudine are summarized in table 1. Sixty-nine percent of the children were recent immigrants from east and southeast Asian countries. The median virus load and ALT level at the start of treatment were copies/mL (range, 1.8 ϫ 10 
HBeAg Clearance during Treatment with Lamivudine
Eight children (50%) achieved suppression of virus load to !10 5 copies/mL and clearance of HBeAg (i.e., responders) ( figure  1A) . Normalization of ALT levels accompanied HBeAg clearance in all 8 children, 7 of whom also achieved HBeAb seroconversion. The median time to seroconversion was 5.3 months (range, 2-11 months). Among the 8 children who did not achieve suppression of virus load to !10 5 copies/mL and clearance of HBeAg (i.e., nonresponders), 5 children (63%) had ALT levels that returned to normal.
Kinetics of the Decrease in Virus Load during Lamivudine Treatment
Lamivudine was associated with a mean virus load reduction (‫ע‬SD) of log 10 copies/mL. Responders tended to 4.8 ‫ע‬ 0.95 have a slightly larger mean virus load reduction (5.2 ‫ע‬ 0.58 log 10 copies/mL) than did nonresponders ( log 10 cop-4.4 ‫ע‬ 1.1 ies/mL;
). The rate of decrease of serum HBV levels P p 0.1 was more rapid during the first month of treatment and, subsequently, leveled off over the next several months ( figure 1A  and 1B) . During the first month of treatment, the virus load decreased at a rate of 3.3 log 10 copies/mL versus 2.7 log 10 copies/ mL among responders and nonresponders, respectively (P p ). During the second month of treatment, the virus load .09 decreased at a mean rate of 0.93 log 10 copies/mL per month among responders and 1.08 log 10 copies/mL per month among nonresponders (
). The median nadir virus load was P p .7 ! copies/mL among responders (range, ! to 2 2 2 ϫ 10 2 ϫ 10 copies/mL) and copies/mL among nonre-2 4
1.6 ϫ 10 7.5 ϫ 10 sponders (range, to copies/mL; ; fig- 3 6 1.1 ϫ 10 5.2 ϫ 10 P ! .001 ure 1A and 1B).
Predictors of HBeAg Clearance
Factors that were associated with HBeAg clearance were evaluated at 2 separate periods of time: before starting therapy (i.e., baseline) and after lamivudine treatment was initiated.
Factors present at the start of therapy that were associated with HBeAg clearance. In univariate analyses, the following 3 factors that were predictive of HBeAg clearance were identified: low pretreatment serum HBV DNA load, high serum ALT level during the year preceding therapy, and older age at the start of therapy (table 2). Differences in HBeAg clearance based on sex and serum ALT levels were not statistically sig- nificant. The 3 variables predictive of HBeAg seroconversion that were identified on the basis of the above univariate analysis (i.e., age, HBV load at baseline, and ALT value within 1 year preceding treatment) were then examined using multivariate analyses. Logistic regression was performed, but the sample size was underpowered to allow for appropriate multivariate analyses. In the discriminant model, however, each of the 3 variables was found to be independently statistically significant for predicting seroconversion ( ). Analysis of the combination P ! .001 of these factors was more successful for predicting subjects who failed to clear HBeAg (specificity, 8 [100%] of 8 individuals) than for subjects who cleared HBeAg (sensitivity, 7 [87.5%] of 8 individuals). The overall accuracy of the classification was 93.75%, with a positive predictive value of 100% (7 of 7 individuals).
Factors associated with HBeAg clearance after initiation of treatment. HBeAg clearance was not associated with the rate at which the virus load decreased but was associated with the achievement of a specific (threshold) level of virus suppression within a specified period of time. This was apparent as early as 1 month after beginning therapy (table 3) . Finally, HBeAg clearance was associated with achievement of a nadir virus load of !1000 HBV copies/mL.
Lamivudine Resistance
Clinical resistance to lamivudine was observed in 3 children (19%) within the first 12 months after initiation of treatment. Lamivudine resistance was observed in 2 more children 112 months after initiation of therapy. Overall, 4 (100%) of 4 children whose nadir virus load during treatment was 110 5 copies/ mL developed resistance, compared with 1 (25%) of 4 children whose nadir virus load was !10 5 copies/mL ( ). P p .07
Durability of Response
Two patients (25%) relapsed within 6 months after discontinuing lamivudine therapy, including the responder who did not develop antibodies to HBeAg. Overall, 6 (37.5%) of the 16 children had achieved a sustained virological response with sustained HBeAg seroconversion and a low virus load (!10,000 copies/mL).
Adverse Events
No adverse events were described by any of the 16 patients or their parents. There were no reports of therapy discontinuation.
DISCUSSION
In this study of 16 children who were chronically infected with HBV, lamivudine treatment resulted in a brisk suppression of serum HBV DNA loads of almost 5 log 10 after 3 months of treatment. This response was similar to findings reported in adult patients [13] . Virus loads decreased in a biphasic manner. A more rapid rate of decrease in the virus load was observed in the first month of therapy that probably reflects the clearance of free HBV virions from the serum [14] . The decrease was followed by a phase in which the virus load decreased at slower rate, which is often attributed to the loss of infected cells as the result of the host HBV-specific immune response [14, 15] . Early clearance of virus may be enhanced by a more robust host immune response. However, in this study, the rates in which the virus loads decreased in responders and nonresponders were not statistically significant or predictive of treatment response. The small sample size may account for the lack of statistical significance between responders and nonresponders in the rates in which virus loads decreased. To achieve adequate power (at least 80%) for an a of 0.05, we would have needed a minimum sample of 26 children with the observed differences in mean virus loads.
In contrast, the level of HBV DNA suppression was significantly correlated with HBeAg clearance. This correlation was apparent as early as 1 month after beginning lamivudine treatment. In this study, the achievement of a level of virus sup- Nadir HBV load, mean copies/mL !2 ϫ 10 pression of !1000 copies/mL was consistently associated with HBeAg clearance, a result that was comparable to results published in studies of lamivudine-treated adults [13] . Conversely, in our study, the failure to achieve a level of virus suppression of !10 5 copies/mL was associated with the development of resistance to lamivudine. The degree of suppression of serum HBV DNA loads 3 months after the initiation of lamivudine therapy has been previously correlated with the maintenance of treatment response [16] and the emergence of drug-resistant HBV strains [17] .
In our study, treatment with lamivudine resulted in HBeAg seroconversion in 50% of the treated children and was always accompanied by normalization of ALT levels and usually by HBeAb seroconversion. Six months after the cessation of treatment, 75% of the children who seroconverted remained HBeAg negative, yielding an overall sustained virological response rate of 37.5%. The sustained virological response rate in this study is slightly higher than those reported in adult and pediatric trials. In studies of adults in the United States and Asia, 16%-18% of patients had achieved HBeAg seroconversion by week 52 of treatment [6, 9, 18] . In a recently completed randomized lamivudine trial in a pediatric population, a 23% clearance rate of HBeAg was observed after 52 weeks of therapy for the treatment group, compared with a clearance rate of 13% in the placebo arm. The higher overall response rate observed in the current study might have been attributed to the large proportion of patients with moderately elevated ALT levels (62.5% had an ALT level of 15 times the upper limit of normal (ULN) within 1 year after the initiation of treatment) and relatively low serum HBV DNA loads (! copies/mL for 62.5% 8 3.5 ϫ 10 of subjects). One-half of these children were adolescents. High pretherapy ALT values and low pretherapy HBV DNA loads have previously been recognized as important determinants for response to therapy, first in studies of IFN and subsequently for lamivudine. Seroconversion rates of 34% and 50% had been previously noted among children with pretherapy ALT levels that were 12 times and 15 times the ULN, respectively [7] . In the study of lamivudine in a population of Asian adults, 64% of patients with an ALT level of 15 times the ULN cleared HBeAg, compared with 5% of patients with !2 times the ULN at baseline [19] . Similarly, pretherapy ALT values and serum HBV DNA loads were identified as significant predictive factors in this study. These 2 factors and the age of the child at the onset of therapy predicted the outcome in nearly 94% of the cases in the current study.
For children infected perinatally or during early childhood, age is an important determinant of the spontaneous rate of HBeAg seroconversion [20] . Spontaneous seroconversion, which is often preceded by increases in ALT levels, most commonly occurs between the ages of 15 and 30 years. Children with an ALT level of 15 times the ULN and an HBV DNA loads of ! copies/mL are likely to clear HBeAg spontaneously 8 5 ϫ 10 within 3 years after onset of hepatitis B, even without treatment [21] . High ALT levels are surrogate markers of host immune responses, particularly the HLA-class I antigen-restricted cytotoxic T lymphocyte response that targets cells expressing HBV antigens [22] . It also has been shown that patients with an acute exacerbation of hepatitis B, reflected by serum ALT levels of 15 times the ULN, have more robust immune responses against HBV than do patients with lower ALT levels [23] . It is no surprise that lamivudine has been associated with the restoration of HBV-specific CD4
+ and CD8 + lymphocyte responses [24, 25] . In clinical practice, however, it is difficult to predict the ALT level and the time at which a particular child will undergo HBeAg seroconversion.
Initial concerns have been raised about the durability of HBeAg seroconversion once lamivudine treatment is discontinued. There have been reported rates of relapse, varying from 19% to 62% [3] . The HBeAg relapse rate for the children in this study was 25%, which is comparable with the 17% relapse rate reported in a placebo-controlled lamivudine trial involving children [7] . Similarly, the rate of clinical drug resistance (19%) reported in our study is consistent with rates reported for adults [26] and children [7] . This study is limited by its retrospective nature and its small sample size. Nonetheless, it has provided a more detailed description of the kinetics of virus load decrease and its relationship to treatment outcome in HBV-infected children. There are clear similarities between the responses observed in children and those reported in adults. The age, ALT level, and virus load of the patient were found to be good predictors of a favorable treatment response to lamivudine before initiating therapy. Once treatment began, the level of virus suppression achieved in the first few months of therapy was an excellent predictor of treatment success. This information may allow the physician to modify therapy early in the course of treatment that might increase the chances of a successful clinical outcome and reduce the chance of developing resistance. Larger studies are needed to confirm these findings and to better define the indications in and management of HBV-infected children receiving lamivudine therapy.
